Insights into EGFR Mutations and Oncogenic KRAS Mutations in Non-Small-Cell Lung Cancer

被引：0
|
作者：
Rosell, Rafael [1 ,2 ]
Aguilar-Hernandez, Andres [2 ]
Gonzalez-Cao, Maria [2 ]
机构：
[1] Germans Trias & Pujol Res Inst, Badalona 08916, Spain
[2] Hosp Quiron Dexeus, IOR, Barcelona 08028, Spain
来源：
CANCERS | 2023年 / 15卷 / 09期
关键词：
KINASE;
D O I：
10.3390/cancers15092519
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [41] Human Papillomavirus in Non-Small-Cell Lung Cancer: The Impact of EGFR Mutations and the Response to Erlotinib
    Marquez-Medina, Diego
    Gasol-Cudos, Ariadna
    Teresa Taberner-Bonastre, M.
    Samame Perez-Vargas, Juan Carlos
    Salud-Salvia, Antonieta
    Llombart-Cussac, Antonio
    ARCHIVOS DE BRONCONEUMOLOGIA, 2013, 49 (02): : 79 - 81
  • [42] Mutation-Specific Antibodies for the Detection of EGFR Mutations in Non-Small-Cell Lung Cancer
    Yu, J.
    Benedettini, E.
    Li, D. Q.
    Gu, T.
    Herebert, H.
    Smith, B.
    Polakiewicz, R.
    Zhou, X. M.
    Loda, M.
    Comb, M.
    MODERN PATHOLOGY, 2009, 22 : 364A - 364A
  • [43] Advanced non-small-cell Lung Cancer (NSCLC) Solid Options for EGFR-Mutations
    Roos, Martin
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 (10) : 639 - 639
  • [44] Effectiveness of icotinib against non-small-cell lung cancer with uncommon EGFR mutations.
    Zhou, Shengyu
    Hu, Xingsheng
    Wang, Yan
    Li Junling
    Zhou, Liqiang
    Hao, Xuezhi
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [45] EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer
    Fang, Wenfeng
    Huang, Yihua
    Hong, Shaodong
    Zhang, Zhonghan
    Wang, Minghui
    Gan, Jiadi
    Wang, Wenjing
    Guo, Honglin
    Wang, Kai
    Zhang, Li
    BMC CANCER, 2019, 19 (1)
  • [46] Mutation-Specific Antibodies for the Detection of EGFR Mutations in Non-Small-Cell Lung Cancer
    Yu, J.
    Benedettini, E.
    Li, D. Q.
    Gu, T.
    Herebert, H.
    Smith, B.
    Polakiewicz, R.
    Zhou, X. M.
    Loda, M.
    Comb, M.
    LABORATORY INVESTIGATION, 2009, 89 : 364A - 364A
  • [47] Treatment of Patients With Non-small-cell Lung Cancer With Uncommon EGFR Mutations in Clinical Practice
    Yamada, Yutaka
    Tamura, Tomohiro
    Yamamoto, Yusuke
    Ichimura, Hideo
    Hayashihara, Kenji
    Saito, Takefumi
    Yamada, Hideyasu
    Endo, Takeo
    Nakamura, Ryota
    Inage, Yoshihisa
    Satoh, Hiroaki
    Iguchi, Kesato
    Saito, Kazuto
    Inagaki, Masaharu
    Kikuchi, Norihiro
    Kurishima, Koichi
    Ishikawa, Hiroichi
    Sakai, Mitsuaki
    Kamiyama, Koichi
    Shiozawa, Toshihiro
    Hizawa, Nobuyuki
    Sekine, Ikuo
    Sato, Yukio
    Funayama, Yasunori
    Miyazaki, Kunihiko
    Kodama, Takahide
    Hayashi, Shigen
    Nomura, Akihiro
    Nakamura, Hiroyuki
    Furukawa, Kinya
    Yamashita, Takaaki
    Okubo, Hatsumi
    Suzuki, Hisashi
    Kiyoshima, Moriyuki
    Kaburagi, Takayuki
    ANTICANCER RESEARCH, 2020, 40 (10) : 5757 - 5764
  • [48] FREQUENCY OF EGFR MUTATIONS IN NON-SMALL-CELL LUNG CANCER (NSCLC) FROM GREEK PATIENTS
    Papadopoulou, E.
    Murray, S.
    Efstathiadou, C.
    Nasioulas, G.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (06) : S35 - S36
  • [49] EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer
    van Zandwijk, N.
    Mathy, A.
    Boerrigter, L.
    Ruijter, H.
    Tielen, I.
    de Jong, D.
    Baas, P.
    Burgers, S.
    Nederlof, P.
    ANNALS OF ONCOLOGY, 2007, 18 (01) : 99 - 103
  • [50] New driver mutations in non-small-cell lung cancer
    Pao, William
    Girard, Nicolas
    LANCET ONCOLOGY, 2011, 12 (02): : 175 - 180
12345